Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25437336 | 0.79 | KMT2A (0.39) | NOTUMKMT2AALDH1A1CAPN1 | |
| SCHEMBL27542306 | 0.79 | SMN1; SMN2 (0.41) | KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7733716 | 0.78 | NOTUM (0.52) | NOTUMKMT2AMEN1CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL25337514 | 0.77 | SMN1; SMN2 (0.40) | KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8946139 | 0.72 | KMT2A (0.60) | NOTUMKMT2AMEN1CYP3A4CYP2C9 | |
| SCHEMBL31222337 | 0.69 | NOTUM (0.49) | NOTUMKMT2AMEN1CYP3A4CYP2C9 | |
| SCHEMBL15540001 | 0.69 | NOTUM (0.45) | NOTUMKMT2AMEN1CYP3A4CYP2C9 | |
| SCHEMBL21653748 | 0.69 | NOTUM (0.45) | NOTUMKMT2AMEN1CYP3A4CYP2C9 | |
| SCHEMBL15539862 | 0.69 | NOTUM (0.49) | NOTUMKMT2AMEN1CYP3A4CYP2C9 | |
| SCHEMBL827169 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | NOTUM 3292/4885KMT2A 2966/4885MEN1 1031/4885 |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | NOTUM 3292/4885KMT2A 2966/4885MEN1 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.